CGTX

Cognition is a clinical-stage biopharma with no product revenue and no approved drug — the entire equity value rides on one asset, zervimesine, in CNS/retina indications (Alzheimer's, dementia with Lewy bodies, geographic atrophy). The MD&A is explicit: since inception in 2007 the company has 'incurred significant operating losses,' carries a $198.6M accumulated deficit, and has funded itself almost entirely with NIA grants and serial equity sales. On the numbers, FY2025 net loss was $23.5M (an improvement from $34.0M, but driven partly by R&D falling 10.8% to $37.2M — i.e. spending less on the one thing that matters, not commercial traction). Operating cash flow was -$24.6M. There is no revenue line in any year FY2021–FY2025, so P/E, P/S and growth-adjusted valuation simply do not apply — you cannot value this on fundamentals, only on an unknowable trial outcome. That places it squarely in 'unknowable risk' territory.

The balance sheet looks superficially clean — $36.8M cash, liabilities/equity of just 0.41x, no meaningful debt — but that solvency is rented, not earned. Against a ~$24.6M annual cash burn, the $36.8M cash buys only ~1.5 years before another raise; the $35.7M of obligated NIA funds extends the runway but is restricted to qualifying grant expenses, not general corporate use. The financing history tells the real story: shares outstanding jumped 44.2% YoY to 89.4M, via a March 2024 follow-on at $1.75, an August 2025 registered direct at $2.05, and 13.6M ATM shares for just $9.4M. With the B. Riley ATM terminated (Dec 2025) and the Lincoln Park equity line expired (March 2026), the company has actually shrunk its committed financing toolkit just as cash runs down — the next raise at ~$1.09 would be brutally dilutive to current holders.